DAX6.693-1,4%  Dow12.801-0,7%  Euro1,3200-0,7% 
ESt502.481-1,7%  Nas2.904-0,8%  Öl117,5-1,0% 
TDax769,9-0,4%  Nikkei8.947-0,6%  Gold1.721-0,5% 
Home > Aktien > Introgen Therapeutics Aktie > Nachrichten zu Introgen Therapeutics

Introgen Therapeutics Aktie [WKN: 936231 / ISIN: US46119F1075]

Kurse + Charts + RealtimeNews + AnalysenFundamentalUnternehmenzugeh. WertpapiereAktion
Kurs + ChartChart (groß)News + AdhocBilanz/GuVTermineZertifikateDepot
Times + SalesChart-AnalyseAnalysenDividende/HVProfilOptionsscheineWatchlist
BörsenplätzeChartvergleichKursziele InsidertradesKnock-outsmyfinanzen
OrderbuchRealtime StuttgartRSS Feed im ForumFondsSenden
HistorischRealtime Push  IR-DatenAnleihen
handeln

Hinweis

Auf dieser Seite finden Sie ALLE Nachrichten zur Introgen Therapeutics Inc.. Links ausgesuchte Top-Nachrichten, rechts weitere Meldungen.

Newssuche

 GO 

ALLE Nachrichten zur Introgen Therapeutics Inc.

05.12.08Introgen Common Stock to be Delisted from the Nasdaq Stock Market
03.12.08Introgen Files Voluntary Chapter 11 Petition to Facilitate Restructuring
03.12.08Introgen Files Voluntary Chapter 11 Petition to Facilitate Restructuring
26.11.08Introgen Restructures Operations to Focus on Revenue-Generating Manufacturing Capabilities
18.11.08Introgen Announces the Transfer of its Listing of Common Stock from the Nasdaq Global Market to the Nasdaq Capital Market
11.11.08Introgen Therapeutics Reports Third Quarter 2008 Financial Results
03.10.08Introgen Receives Notification from Nasdaq
05.09.08Introgen Receives Staff Determination Letter from Nasdaq Global Market
02.09.08Introgen Receives Notice ADVEXIN(R) U.S. BLA Not Sufficiently Complete to File
07.08.08Introgen Therapeutics Reports Second Quarter 2008 Financial Results and Recent Corporate Highlights
01.08.08Introgen Receives Nasdaq Notice Regarding Minimum Market Value of Listed Securities
23.07.08ADVEXIN(R) Shows Statistically Significant Six-Month and Overall Survival Benefit as Compared to Methotrexate in Prospectively Defined Biomarker Patient Population
17.07.08Introgen to Present ADVEXIN Phase 3 Study Results at American Association for Cancer Research's Cancer Clinical Trials and Personalized Medicine Conference
03.07.08Introgen Reduces Development Staff to Focus on Commercial Activities after ADVEXIN Regulatory Filings in U.S. and Europe
11.06.08Introgen Creates Technical Services Company and Announces Strategic Alliance with Texas A&M University System to Expand GMP Manufacturing Programs
30.05.08ADVEXIN(R) verbessert Überlebenszeit von Patienten mit rezidivierendem, refraktärem Kopf- und Halskrebs
29.05.08ADVEXIN(R) Pivotal Phase III Data Presented as Part of Late-Breaking ASGT Presentation
29.05.08Correction to Press Release Dated May 28, 2008: ADVEXIN(R) Improves Survival in Recurrent, Refractory Head and Neck Cancer Patients
29.05.08Introgen Presents Top Line Data from Phase III ADVEXIN(R) Clinical Trial
28.05.08ADVEXIN(R) Improves Survival in Recurrent, Refractory Head and Neck Cancer Patients
12.05.08CORRECTING and REPLACING Introgen Therapeutics Reports First Quarter 2008 Financial Results
12.05.08Introgen Therapeutics Reports First Quarter 2008 Financial Results
13.02.08Introgen's p53 Immunotherapy INGN 225 Begins Randomized, Controlled Clinical Trial in Patients with Small Cell Lung Cancer
11.02.08Introgen Therapeutics, Inc. to Present at BIO CEO & Investor Conference
17.01.08Introgen Strengthens Cash Position, Sells Shares in Silence Therapeutics plc
20.12.07Introgen Plans to Expand Biomarker Database in Phase 3 Trials and File BLA and MAA for ADVEXIN in Advanced Head and Neck Cancer in First Half of 2008
27.11.07Gendux gibt bekannt, dass der Marktzulassungsantrag für sein Medikament ADVEXIN von der EMEA zur Überprüfung angenommen wurde
27.11.07Introgen's ADVEXIN Advances as Marketing Authorization Application is Accepted for Review in Europe
27.11.07Gendux Announces Acceptance of Its ADVEXIN Marketing Authorization Application for Review by the EMEA
15.11.07Introgen Therapeutics Highlights Summary ADVEXIN Data at the Third International Workshop on Mutant p53 and the Symposium on Li-Fraumeni Syndrome
13.11.07Introgen and Gendux Submit First Marketing Authorization Application for ADVEXIN
09.11.07Introgen Therapeutics Reports Third Quarter 2007 Financial and Corporate Results
27.09.07Introgen Presents Biomarker Data Demonstrating Abnormal p53 Predicts ADVEXIN Efficacy in Head and Neck, Lung, Prostate and Li-Fraumeni Cancers
06.09.07Introgen's p53 Immunotherapy Drug Candidate to Advance Into Second Phase 2 Clinical Trial in Small Cell Lung Cancer With National Cancer Institute
29.08.07Introgen Therapeutics, Inc. to Present at Thomas Weisel Healthcare Conference
07.08.07Introgen Therapeutics, Inc. to Present at Canaccord Adams' 27th Global Growth Conference
06.08.07Introgen Therapeutics Reports Second Quarter 2007 Financial and Corporate Results
02.08.07Introgen to Host Conference Call to Review Second Quarter Results, Pipeline Progress and Registration Activities for ADVEXIN
17.07.07Introgen Obtains Exclusive US Patent for Development of Adenoviral Vector Based Gene Therapies
02.07.07Introgen Receives Broad U.S. Patent for Improved Storage-Stable Formulations of its Adenoviral-Based Pharmaceuticals

Anzeige

ANZEIGE

 
Wie bewerten Sie diese Seite?
schlecht sehr gut
Aktien Prime Standard: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z DAX MDAX Dow Jones EuroStoxx

Kontakt - Impressum - Werben - Presse

finanzen.net als Startseite - Sitemap - Arbeiten bei finanzen.net - RSS-Feeds - Datenschutz - Disclaimer - Nutzungsbedingungen


Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Telekurs. Verzögerung Deutsche Börse: 15 Min., Nasdaq, NYSE: 20 Min. © 1999-2012 finanzen.net GmbH

News Aktien Kurslisten Analysen Devisen Dollarkurs Fonds Zertifikate Optionsscheine Anleihen Rohstoffe Aktien kaufen Portfolio Links Aktien China Währungsrechner Gold kaufen CFD Aktienkurse Ölpreis Leitzins Heizölpreis IPO Börsenkurse Lexikon